View ValuationXlife Sciences 향후 성장Future 기준 점검 0/6Xlife Sciences 의 수익은 연간 6.9% 감소할 것으로 예상되는 반면, 연간 수익은 2.5% 로 증가할 것으로 예상됩니다. EPS는 연간 11.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -12.5% 로 예상됩니다.핵심 정보-6.9%이익 성장률11.50%EPS 성장률Life Sciences 이익 성장51.3%매출 성장률2.5%향후 자기자본이익률-12.50%애널리스트 커버리지Low마지막 업데이트31 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Aug 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.9% per year for the foreseeable future. Revenue is less than US$1m (CHF275k revenue, or US$340k). Minor Risk Share price has been volatile over the past 3 months (9.9% average weekly change).New Risk • May 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (CHF275k revenue, or US$350k). Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. President of the Board of Directors David Deck was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Dec 10Grupo Landsteiner, S.A. de C.V. y Subsidiarias signed a binding framework agreement to acquire 12 advanced biotech, medtech and digital health projects from Xlife Sciences AG (SWX:XLS) for $450 million.Grupo Landsteiner, S.A. de C.V. y Subsidiarias signed a binding framework agreement to acquire 12 advanced biotech, medtech and digital health projects from Xlife Sciences AG (SWX:XLS) for $450 million on December 8, 2025. A cash consideration of $450 million will be paid by Grupo Landsteiner, S.A. de C.V. y Subsidiarias.공고 • Oct 17Xlife Sciences AG to Report First Half, 2026 Results on Sep 24, 2026Xlife Sciences AG announced that they will report first half, 2026 results on Sep 24, 2026공고 • Sep 24Xlife Sciences AG to Report Fiscal Year 2025 Results on Apr 28, 2026Xlife Sciences AG announced that they will report fiscal year 2025 results on Apr 28, 2026공고 • Jun 04Xlife Sciences AG, Annual General Meeting, Jun 24, 2025Xlife Sciences AG, Annual General Meeting, Jun 24, 2025, at 14:00 W. Europe Standard Time. Location: zurich Switzerland공고 • Sep 19+ 1 more updateXlife Sciences AG to Report Q2, 2025 Results on Sep 23, 2025Xlife Sciences AG announced that they will report Q2, 2025 results on Sep 23, 2025Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CHF37.10, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 37x in the Life Sciences industry in Europe.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 143% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1,607% net profit margin). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Revenue is less than US$5m (CHF1.0m revenue, or US$1.1m).Board Change • Apr 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Desiree Dosch was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Oct 19+ 1 more updateXlife Sciences AG to Report First Half, 2024 Results on Sep 19, 2024Xlife Sciences AG announced that they will report first half, 2024 results on Sep 19, 2024이익 및 매출 성장 예측BATS-CHIXE:XLSZ - 애널리스트 향후 추정치 및 과거 재무 데이터 (CHF Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20280-2711112/31/20270-2711112/31/20260-2711112/31/20250-22-1-1N/A9/30/202515-1-1N/A6/30/202513100N/A3/31/202513300N/A12/31/202413400N/A9/30/202412811N/A6/30/202412122N/A3/31/202411811N/A12/31/202311500N/A9/30/2023116-2-2N/A6/30/2023116-4-4N/A3/31/2023115-4-4N/A12/31/2022114-5-5N/A9/30/2022132-6-5N/A6/30/2022149-7-5N/A3/31/2022151-6-5N/A12/31/2021153-6-4N/A9/30/2021134-4-3N/A6/30/2021114-2-2N/A3/31/2021018-1-1N/A12/31/2020021-10N/A9/30/2020014-1-1N/A6/30/202016-1-1N/A3/31/202013-1-1N/A12/31/20191100N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: XLSZ 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: XLSZ 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: XLSZ 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: XLSZ 의 수익(연간 2.5%)이 UK 시장(연간 4%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: XLSZ 의 수익(연간 2.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: XLSZ는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/08 19:48종가2026/08/06 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Xlife Sciences AG는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Martial DescouturesODDO BHF Corporate & MarketsDaniel JelovcanStifel, Equities ResearchUlrich HuwaldWarburg Research GmbH
New Risk • Aug 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.9% per year for the foreseeable future. Revenue is less than US$1m (CHF275k revenue, or US$340k). Minor Risk Share price has been volatile over the past 3 months (9.9% average weekly change).
New Risk • May 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (CHF275k revenue, or US$350k). Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. President of the Board of Directors David Deck was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Dec 10Grupo Landsteiner, S.A. de C.V. y Subsidiarias signed a binding framework agreement to acquire 12 advanced biotech, medtech and digital health projects from Xlife Sciences AG (SWX:XLS) for $450 million.Grupo Landsteiner, S.A. de C.V. y Subsidiarias signed a binding framework agreement to acquire 12 advanced biotech, medtech and digital health projects from Xlife Sciences AG (SWX:XLS) for $450 million on December 8, 2025. A cash consideration of $450 million will be paid by Grupo Landsteiner, S.A. de C.V. y Subsidiarias.
공고 • Oct 17Xlife Sciences AG to Report First Half, 2026 Results on Sep 24, 2026Xlife Sciences AG announced that they will report first half, 2026 results on Sep 24, 2026
공고 • Sep 24Xlife Sciences AG to Report Fiscal Year 2025 Results on Apr 28, 2026Xlife Sciences AG announced that they will report fiscal year 2025 results on Apr 28, 2026
공고 • Jun 04Xlife Sciences AG, Annual General Meeting, Jun 24, 2025Xlife Sciences AG, Annual General Meeting, Jun 24, 2025, at 14:00 W. Europe Standard Time. Location: zurich Switzerland
공고 • Sep 19+ 1 more updateXlife Sciences AG to Report Q2, 2025 Results on Sep 23, 2025Xlife Sciences AG announced that they will report Q2, 2025 results on Sep 23, 2025
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CHF37.10, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 37x in the Life Sciences industry in Europe.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 143% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1,607% net profit margin). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Revenue is less than US$5m (CHF1.0m revenue, or US$1.1m).
Board Change • Apr 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Desiree Dosch was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Oct 19+ 1 more updateXlife Sciences AG to Report First Half, 2024 Results on Sep 19, 2024Xlife Sciences AG announced that they will report first half, 2024 results on Sep 19, 2024